BloggingStocks http://www.bloggingstocks.com BloggingStocks http://www.blogsmithmedia.com/http://www.bloggingstocks.com/media/feedlogo.gif BloggingStocks http://www.bloggingstocks.com en-us Copyright 2012 Weblogs, Inc. The contents of this feed are available for non-commercial use only. Blogsmith http://www.blogsmith.com/<![CDATA[Despite positive trial results, Amylin Pharmaceuticals faces multiple headwinds]]>http://www.bloggingstocks.com/2009/07/09/despite-positive-trial-results-amylin-pharmaceuticals-faces-mul/http://www.bloggingstocks.com/2009/07/09/despite-positive-trial-results-amylin-pharmaceuticals-faces-mul/http://www.bloggingstocks.com/2009/07/09/despite-positive-trial-results-amylin-pharmaceuticals-faces-mul/#commentsFiled under: ,

Amylin Pharmaceuticals Inc. (NASDAQ: AMLN) caught an early morning boost after reporting positive results from its obesity drug trials. A mid-stage study of its pramlintide/metreleptin combination product revealed no significant side effects on a cardiovascular or neuropsychiatric level, and patients treated with the highest dose experienced much greater weight loss than those participants treated with a placebo.

AMLN was up more than 2% at its intraday peak, but the equity has since pulled back near the break-even line. The stock settled Wednesday below its 20-day moving average for the first time in more than a month, and it has been unable today to reclaim a foothold above this trendline. Meanwhile, stubborn resistance from the $14 region looms not far overhead.

Continue reading Despite positive trial results, Amylin Pharmaceuticals faces multiple headwinds

Despite positive trial results, Amylin Pharmaceuticals faces multiple headwinds originally appeared on BloggingStocks on Thu, 09 Jul 2009 14:40:00 EST. Please see our terms for use of feeds.

Permalink | Email this | Comments]]>AMLNAmylin Pharmaceuticalsinthenewsobesity drugoptionsshort sellerstechnical analysistrial resultsThu, 09 Jul 2009 14:40:00 EST